Tag: biosimilars billing
Biosimilars are billed differently than generics under Medicare Part B. Each has its own HCPCS code and payment rate based on its ASP plus 6% of the reference product’s price. This system encourages biosimilar entry but doesn’t strongly incentivize switching. Learn how billing works and why adoption remains low in the U.S.
Medications
Archives
Recent-posts
Malaria in the United States: Current Risks, Stats, and Prevention
Oct, 3 2025
Packaging and Labeling: How to Verify the Authenticity of Generic Medicines
Jan, 15 2026
Gastritis and H. pylori: What Causes It, How It’s Treated, and What You Need to Know
Dec, 31 2025
How Generic Drugs Saved the U.S. Healthcare System $3.4 Trillion
May, 25 2026
Alternatives to Sumatriptan: Exploring the Options for Migraine Relief
Mar, 28 2025